Russia Registers Nimotuzumab-Based Cancer Drug Nimolancim

Russia's Ministry of Health registered Nimolancim (INN: Nimotuzumab) for treating malignant tumors including esophageal, head and neck, and certain brain tumors. This is a regulatory approval, not a clinical trial result; efficacy and availability remain to be seen. It signals Russia's continued development of domestic oncology drugs amid sanctions.